hypercholesterolemia

Predicted pathogenic mutations in STAP1 are not associated with clinically defined familial hypercholesterolemia.

Related Articles Predicted pathogenic mutations in STAP1 are not associated with clinically defined familial hypercholesterolemia. Atherosclerosis. 2019 Nov 29;292:143-151 Authors: Lamiquiz-Moneo I, Restrepo-Córdoba MA, Mateo-Gallego R, Bea AM, Del Pino...

Read more
Reply: Familial Hypercholesterolemia Causes Sudden Death

Reply: Familial Hypercholesterolemia Causes Sudden Death Source link

Read more
Familial Hypercholesterolemia Causes Sudden Death

Familial Hypercholesterolemia Causes Sudden Death Source link

Read more
Unmet LDL-C Goals Common in ASCVD: PINNACLE, NHANES

Two studies of patients with ASCVD -- NHANES and the PINNACLE registry -- show 'a large burden of non- and undertreatment' and 'room for improvement' to lower LDL-C levels, say...

Read more
Long-Term Efficacy and Safety of Evolocumab in Patients With Hypercholesterolemia

AbstractBackground Evolocumab and other anti-PCSK9 antibodies reduced adverse cardiovascular outcomes in clinical trials of high-risk patients over <3 years median treatment duration. Objectives The OSLER-1 trial (Open Label Study of Long...

Read more
Prevalence of hypercholesterolemia in Nigeria: a systematic review and meta-analysis.

Related Articles Prevalence of hypercholesterolemia in Nigeria: a systematic review and meta-analysis. Public Health. 2019 Nov 04;178:167-178 Authors: Adeloye D, Abaa DQ, Owolabi EO, Ale BM, Mpazanje RG, Dewan MT,...

Read more
Theabrownin from Pu-erh tea attenuates hypercholesterolemia via modulation of gut microbiota and bile acid metabolism

Theabrownin from Pu-erh tea attenuates hypercholesterolemia via modulation of gut microbiota and bile acid metabolism Source link

Read more
Evolocumab Treatment of Hypercholesterolemia in OSLER-1: Enduring Efficacy, Tolerability, and Safety Over 5 Years

Evolocumab Treatment of Hypercholesterolemia in OSLER-1: Enduring Efficacy, Tolerability, and Safety Over 5 Years Source link

Read more
Long-Term Benefit of Early Statin Therapy for Familial Hypercholesterolemia

Improved low-density lipoprotein levels and reduced cardiovascular event risk were shown after 20 years of statin treatment in children with FH. Source link

Read more
Longitudinal low density lipoprotein cholesterol goal achievement and cardiovascular outcomes among adult patients with familial hypercholesterolemia: The CASCADE FH registry.

Related Articles Longitudinal low density lipoprotein cholesterol goal achievement and cardiovascular outcomes among adult patients with familial hypercholesterolemia: The CASCADE FH registry. Atherosclerosis. 2019 Aug 19;289:85-93 Authors: Duell PB, Gidding...

Read more
Cholesterol lowering attenuates pressure overload-induced heart failure in mice with mild hypercholesterolemia.

Related Articles Cholesterol lowering attenuates pressure overload-induced heart failure in mice with mild hypercholesterolemia. Aging (Albany NY). 2019 Sep 04;11: Authors: Muthuramu I, Mishra M, Aboumsallem JP, Postnov A, Gheysens...

Read more
Polygenic Risk Scores in Familial Hypercholesterolemia

Polygenic Risk Scores in Familial Hypercholesterolemia Source link

Read more
Risk of Premature Atherosclerotic Disease in Patients With Monogenic Versus Polygenic Familial Hypercholesterolemia

AbstractBackground A pathogenic variant in LDLR, APOB, or PCSK9 can be identified in 30% to 80% of patients with clinically-diagnosed familial hypercholesterolemia (FH). Alternatively, ~20% of clinical FH is thought...

Read more
'Double Whammy': Where do PCSK9 Inhibitors Fit for Diabetes/ACS?

Patients with diabetes as well as ACS and uncontrolled high cholesterol have a "double whammy" that makes them candidates for PCSK9 inhibitors to prevent CV events, says expert. Medscape Medical...

Read more
A bacterium may limit cardiovascular risks of 1 in 2 people, study shows

In 2007, Patrice Cani (FNRS-WELBIO researcher) and his team at the Louvain Drug Research Institute of University of Louvain, in close collaboration with Willem de Vos, professor at UWageningen, discovered...

Read more
The Impact of the International Cooperation On Familial Hypercholesterolemia Screening and Treatment: Results from the ScreenPro FH Project.

The Impact of the International Cooperation On Familial Hypercholesterolemia Screening and Treatment: Results from the ScreenPro FH Project. Curr Atheroscler Rep. 2019 Jun 22;21(9):36 Authors: Ceska R, Latkovskis G, Ezhov...

Read more
Hypercholesterolemia Among Premature Infarcts: Time to Start the Clock of Familial Hypercholesterolemia Assessment

[ad_1] Hypercholesterolemia Among Premature Infarcts: Time to Start the Clock of Familial Hypercholesterolemia Assessment Source link [ad_2]

Read more
Familial Hypercholesterolemia Among Young Adults With Myocardial Infarction

[ad_1] AbstractBackground There are limited data on the prevalence and treatment of familial hypercholesterolemia (FH) among U.S. adults who experience a myocardial infarction (MI) at a young age. Objectives This...

Read more
Machine learning IDs risk for familial hypercholesterolemia

[ad_1] (HealthDay)—A machine learning classifier can effectively identify patients at risk for familial hypercholesterolemia (FH), according to a study published online April 11 in npj Digital Medicine. Source link [ad_2]

Read more
Success for new cholesterol-lowering drug

[ad_1] A new, oral drug that effectively lowers LDL or "bad" cholesterol, looks set for clinical approval. Source link [ad_2]

Read more